The ON-SITE study represents a prospective, observational study focused on the training/tuning and pivotal validation of deep learning algorithms that detect cell/tissue morphology suspicious for cancer in biopsies of peripheral lung nodules/masses and mediastinal/hilar lymph nodes imaged with the NIO Laser Imaging System in the procedure room without requiring traditional sample processing.
The study includes four arms based on biopsy location and biopsy modality/tool:
1. Transbronchial forceps biopsy of peripheral lung nodules/masses (peripheral-TBBx) 2. Transbronchial needle aspiration biopsy of peripheral lung nodules/masses (peripheral TBNA) 3. Transbronchial needle aspiration biopsy of mediastinal/hilar lymph nodes (EBUS-TBNA) 4. Transbronchial cryo biopsy of peripheral lung nodules/masses (peripheral-CBx)
The patient or legal guardian is willing and able to understand, sign and date the Ethics committee approved study specific Informed Consent Form.
The patient is 22 years of age or older.
The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion.
The patient can tolerate the clinical procedure as indicated.
Patient is a prisoner.
The participant, in the judgment of the Investigator, may be inappropriate for the intended study procedures
Invenio Imaging Inc.
Lead sponsor
Memorial Sloan Kettering Cancer Center
Collaborator
University of North Carolina, Chapel Hill
Collaborator
M.D. Anderson Cancer Center
Collaborator
Mayo Clinic
Collaborator
University of California, San Diego
Collaborator
Montefiore Medical Center-Moses-Weiler
Collaborator
Corewell Health
Collaborator